Janssen Reports Positive 2-Year Results for Stelara as Crohn’s Treatment

Janssen Reports Positive 2-Year Results for Stelara as Crohn’s Treatment
Janssen-Cilag International reported results from its ongoing IM-UNITI long-term extension (LTE) clinical trial assessing the efficacy and safety of subcutaneous (SC) Stelara (ustekinumab) in patients with moderate to severe Crohn’s disease. The company, a division of Johnson & Johnson, presented the study’s two-year results at the 12th Congress of the European Crohn’s and Colitis Organisation, and

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *